




PHARMACEUTICAL 2021

Cell Source Inc.
Rank 383 of 402





PHARMACEUTICAL 2021

Cell Source Inc.
Rank 383 of 402

The relative strengths and weaknesses of Cell Source Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cell Source Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 249% points. The greatest weakness of Cell Source Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 265% points.

The company's Economic Capital Ratio, given in the ranking table, is -412%, being 459% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,400
Liabilities, Non-Current	0
Other Assets	452
Other Compr. Net Income	0
Other Expenses	164
Other Liabilities	0
Other Net Income	-922
Other Revenues	0
Property and Equipment	0
Research and Development	835
Selling, General and Administrative Expense	2,639

Output Variable	Value in 1000 USD
Assets	452
Liabilities	8,400
Expenses	3,638
Revenues	0
Stockholders Equity	-7,947
Net Income	-4,560
Comprehensive Net Income	-4,560
Economic Capital Ratio	-412%